Categories AlphaGraphs, Earnings, Technology

Snap’s new design brought an ugly result

Snap Inc. (SNAP) reported its first quarter 2018 results on Tuesday which were not impressive enough despite growth in both consolidated and advertising revenues. Shares took a sharp dive downwards following the results. Snap’s redesign of its Snapchat app has not gone down well with users and the company appears to be pondering a change of plan. Snap stock plummeted around 20% today.

The social media company saw slower growth in daily active users during the first quarter versus the fourth quarter. CEO Evan Spiegel said the company will tweak the new design in such a way that users would find satisfactory. He added that Snap is rebuilding the app for its Android users who are experiencing much more difficulty post the new design.

Analysts seem to be divided on Snap’s upcoming stock performance. Some analysts believe the stock will underperform even though its revenue growth rate is similar to that of Facebook (FB). There are others who hold an outperform rating encouraged by the company’s new product initiatives. Several analysts have cut their price targets.

Analysts are predicting that mismanagement would have a negative impact Snap’s advertising business and lack of sufficient investments would hold Snap back while Instagram continues its rapid growth. Instagram reported a 63% increase in profit along with growth in users last week. Some analysts do not expect Snap to generate positive cash flow until 2022.

Snap’s new software-based auction system for its advertising business will hurt revenue in the short term as this system makes it less expensive to buy ads on Snapchat. Ad prices dropped 65% year-over-year during the first quarter.

Earlier this year, Kylie Jenner knocked off $1 billion from Snap’s value with a single tweet. The earnings release appears to have taken out another $4 billion from its value. Snap needs to get into full damage control to pick itself back up again and do so fast.

Snapchat parent Snap Inc Q1 2018 Earnings Infographic

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated


Add Comment
Viewing Highlight